Table 2.

Ongoing clinical trials with RET-inhibitors enrolling breast cancer patients.

Disease	Trial Identifier	Intervention	Regimens	Phase	Endpoints
HR+/HER2- breast cancer	NCT05181033	Lenvatinib + Letrozole vs Fulvestrant	14 mg daily + 2.5 mg daily vs 500 mg day 1 every 4-weekly cycle	II	PFS, ORR, CBS, OS
HR+/HER2- breast cancer	NCT05286437	Lenvatinib + Letrozole + Pembrolizumab	14 mg daily + 2.5 mg daily + 400 mg day 1 every 6-weekly cycle	II	ORR, PFS, DOR, CBR, OD
HR+/HER2- breast cancer	NCT05075512	Anlotinib + Fulvestrant	12 mg once daily on days 1-14, every 21 days + 500 mg day 1 every 4-weekly cycle	II	PFS, ORR, CBR, OS, AE
Advanced solid tumors RET fusion + solid tumors MTC	NCT03157128	Selpercatinib	20 mg once daily or 20-240 mg twice/160 twice	I/II	ORR, OS, PFS, DOR

PFS, progression-free survival; ORR, overall response rate; DFS, disease-free survival; OS, overall survival; CBR, clinical benefit rate; DOR, duration of response; AE, adverse event.